U.S. Markets closed

Does Market Volatility Impact Marker Therapeutics, Inc.’s (NASDAQ:MRKR) Share Price?

Saundra Reilly

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

Anyone researching Marker Therapeutics, Inc. (NASDAQ:MRKR) might want to consider the historical volatility of the share price. Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. The first type is company specific volatility. Investors use diversification across uncorrelated stocks to reduce this kind of price volatility across the portfolio. The second type is the broader market volatility, which you cannot diversify away, since it arises from macroeconomic factors which directly affects all the stocks on the market.

Some stocks are more sensitive to general market forces than others. Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). However, Warren Buffett said ‘volatility is far from synonymous with risk’ in his 2014 letter to investors. So, while useful, beta is not the only metric to consider. To use beta as an investor, you must first understand that the overall market has a beta of one. A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market. In comparison a stock with a beta of over one tends to be move in a similar direction to the market in the long term, but with greater changes in price.

Check out our latest analysis for Marker Therapeutics

What MRKR’s beta value tells investors

Zooming in on Marker Therapeutics, we see it has a five year beta of 0.80. This is below 1, so historically its share price has been rather independent from the market. If history is a good guide, owning the stock should help ensure that your portfolio is not overly sensitive to market volatility. Beta is worth considering, but it’s also important to consider whether Marker Therapeutics is growing earnings and revenue. You can take a look for yourself, below.

NASDAQCM:MRKR Income Statement Export February 4th 19

Could MRKR’s size cause it to be more volatile?

Marker Therapeutics is a rather small company. It has a market capitalisation of US$238m, which means it is probably under the radar of most investors. Companies with market capitalisations around this size often show poor correlation with the broader market because market volatility is overshadowed by company specific events, or other factors. It’s worth checking to see how often shares are traded, because very small companies with very low beta values are often only thinly traded.

What this means for you:

Since Marker Therapeutics is not heavily influenced by market moves, its share price is probably far more dependend on company specific developments. It could pay to take a closer look at metrics such as revenue growth, earnings growth, and debt. In order to fully understand whether MRKR is a good investment for you, we also need to consider important company-specific fundamentals such as Marker Therapeutics’s financial health and performance track record. I urge you to continue your research by taking a look at the following:

  1. Future Outlook: What are well-informed industry analysts predicting for MRKR’s future growth? Take a look at our free research report of analyst consensus for MRKR’s outlook.
  2. Past Track Record: Has MRKR been consistently performing well irrespective of the ups and downs in the market? Go into more detail in the past performance analysis and take a look at the free visual representations of MRKR’s historicals for more clarity.
  3. Other Interesting Stocks: It’s worth checking to see how MRKR measures up against other companies on valuation. You could start with this free list of prospective options.

To help readers see past the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price-sensitive company announcements.

The author is an independent contributor and at the time of publication had no position in the stocks mentioned. For errors that warrant correction please contact the editor at editorial-team@simplywallst.com.